SCHEMBL2463166

SCHEMBL2463166

C[C@@H](N)CN1CCN(c2cccc(O)c2)[C@@H](C)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 6/20 0.60
MAPK1 P28482 3/20 0.47
MAPT P10636 6/20 0.44
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
DRD2 P14416 3/20 0.42
DRD3 P35462 2/20 0.39
KDM4E B2RXH2 3/20 0.38
HTT P42858 2/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TP53 P04637 2/20 0.38
LMNA P02545 1/20 0.37
GLA P06280 1/20 0.37
TSHR P16473 1/20 0.37
GFER P55789 2/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12335905 0.90 OPRM1 (0.57) OPRM1MAPK1MAPTESR1ESR2
SCHEMBL2466252 0.90 OPRM1 (0.57) OPRM1MAPK1MAPTESR1ESR2
SCHEMBL16541858 0.88 OPRM1 (0.60) OPRM1MAPK1MAPTESR1ESR2
SCHEMBL16541859 0.83 OPRM1 (0.55) OPRM1MAPK1MAPTESR1ESR2
SCHEMBL28436447 0.81 OPRM1 (0.70) OPRM1MAPK1DRD2DRD3DRD4
SCHEMBL21227034 0.81 OPRM1 (0.70) OPRM1MAPK1DRD2DRD3DRD4
SCHEMBL29914715 0.81 OPRM1 (0.70) OPRM1MAPK1DRD2DRD3DRD4
SCHEMBL19052403 0.78 OPRM1 (0.66) OPRM1MAPK1MAPTDRD2DRD3
SCHEMBL2467386 0.76 OPRM1 (0.60) OPRM1MAPK1ESR1ESR2DRD2
SCHEMBL13836265 0.76 OPRM1 (0.60) OPRM1MAPK1ESR1ESR2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9750738-B2 Arylpiperazine opioid receptor antagonists RESEARCH TRIANGLE INSTITUTE (US) 2017-09-05 US disclosed
US-20160095854-A1 ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS RESEARCH TRIANGLE INSTITUTE (US) 2016-04-07 US disclosed
US-9273027-B2 Arylpiperazine opioid receptor antagonists RESEARCH TRIANGLE INSTITUTE (US) 2016-03-01 US disclosed
EP-2539706-B1 ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS RES TRIANGLE INST (US) 2015-03-04 EP disclosed
EP-2539706-A1 ARYLPIPERAZONE OPIOID RECEPTOR ANTAGONISTS Research Triangle Institute (US) 2013-01-02 EP disclosed
US-20120295919-A1 ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS RESEARCH TRIANGLE INSTITUTE (US) 2012-11-22 US disclosed
WO-2011106039-A1 ARYLPIPERAZONE OPIOID RECEPTOR ANTAGONISTS RESEARCH TRIANGLE INSTITUTE (US) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295919-A1 ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS OPRL1, OPRM1, OPRD1 OPRM1 2/4885MAPK1 2791/4885MAPT 3852/4885
US-20160095854-A1 ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS OPRL1, OPRM1, OPRD1 OPRM1 2/4885MAPK1 2718/4885MAPT 3851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.